Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors.
MetadataShow full item record
AuthorArias, Fabio; Franco Moltabán, Francisco; Romero Pérez, Miguel; Carrión Peregrina, María Dora; Camacho Quesada, Encarnación
Drug designInhibitorsImidamidesNitric Oxide SynthaseSynthesis
F. Arias et al. Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors. Bioorganic & Medicinal Chemistry 44 (2021) 116294. [https://doi.org/10.1016/j.bmc.2021.116294]
SponsorshipCSIRC; Centro de Supercomputación de la Universidad de Granada; Granada University Library; European Commission; Ministerio de Economía y Competitividad SAF2017-84894-R; Instituto de Salud Carlos III; Comisión Interministerial de Ciencia y Tecnología
In search of new Nitric Oxide Synthase (NOS) inhibitor agents, two isosteric series of derivatives with an imidamide scaffold (one of them with a hydroxyl group and the other with a carbonyl one) were synthesized and evaluated on inducible (iNOS) and neuronal (nNOS) isoforms. These compounds have been designed by combining a kynurenamine framework with an amidine moiety in order to improve selectivity for the inducible isoform. In general, the in vitro inhibitory assays exhibited better inhibition values on the iNOS isoform, being the N-(3-(2-amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimidamide 4i the most active inhibitor with the highest iNOS selectivity, without inhibiting eNOS. Docking studies on the two most active compounds suggest a different binding mode on both isozymes, supporting the experimentally observed selectivity towards the inducible isoform. Physicochemical in silico studies suggest that these compounds possess good drug-likeness properties.